Pertaining to Ca2+ handling abnormalities, autoantibodies targeting the N-terminus of the L-type voltage-gated Ca2+ channel (Cav1.2, α1c pore-forming subunit or CACNA1c) are present in 49% of patients with dilated cardiomyopathy [22]. The gene discussed is CACNA1C; the disease is dilated cardiomyopathy.